About Ai2

About Ai2 Header

Ai2 Ltd was founded in 2005 as a spin-out company from the University of Manchester to develop and commercially exploit the anti-infective peptide technology identified by founder Dr. Curtis Dobson.

Since its foundation Ai2 has grown into a successful SME funded through private investment and grant funding with a strong IP portfolio.

Ai2 has focussed on developing the technology in the area of medical devices, in particular ophthalmics. With a licence deal signed for application of Ai2 peptide technology in this area Ai2 is now expanding its focus to other medical device applications and to areas outside the medical device sector including oral care, personal care and advanced wound care.